- Home
- CNK vs CELC Comparison
CNK vs CELC Comparison
Compare CNK & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNK | CELC |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNK | CELC |
|---|---|---|
| Price | $25.76 | $113.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $32.90 | ★ $106.63 |
| AVG Volume (30 Days) | ★ 2.6M | 527.9K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $3,115,000,000.00 | N/A |
| Revenue This Year | $10.82 | N/A |
| Revenue Next Year | $3.68 | N/A |
| P/E Ratio | $24.50 | ★ N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $21.60 | $7.58 |
| 52 Week High | $34.01 | $120.32 |
Technical Indicators
Market Signals| Indicator | CNK | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 56.01 |
| Support Level | $24.84 | $97.75 |
| Resistance Level | $27.45 | $114.54 |
| Average True Range (ATR) | 0.89 | 5.14 |
| MACD | -0.31 | 0.36 |
| Stochastic Oscillator | 12.34 | 63.53 |
Price Performance
Historical ComparisonAbout CNK Cinemark Holdings Inc Cinemark Holdings Inc.
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.